WuXi Biologics (2269) investor relations material

Business model and growth strategy

• Operates a scaled, integrated CRDMO platform offering end-to-end biologics services, including discovery, development, and commercial manufacturing.

• Focuses on complex modalities such as bispecifics, multi-specifics, and ADCs, which now make up two-thirds of the portfolio and are the fastest-growing segments.

• Achieved a record high of 209 new integrated projects signed last year, with a pipeline approaching 1,000 active programs and about half of new projects from U.S. clients.

• Royalty, milestone, and upfront payments are a growing profit driver, expected to reach 25% of profit in five years, with potential milestones exceeding $4B.

• Maintains a high manufacturing and regulatory success rate, including 98-99% manufacturing success and 100% BLA and global regulatory inspection approval.

Financial performance and outlook

• Biotech contract value from last year reached $4 billion, with 20% of profit now from royalty and milestone payments.

• Bispecifics and multi-specifics revenue grew from 4-5% to nearly 20% in three years, with over 120% annual growth.

• Manufacturing revenue is expected to accelerate, with PPQ numbers tripling and 99% success rate; 28 PPQs completed in 2025 and 34 scheduled for 2026.

• Qatar site projected to contribute $500–$800 million in revenue by 2030.

• Milestone and upfront payments expected to grow at a 30% CAGR, supporting margin expansion.

Technology and innovation

• Invested early in bispecific, CD3, and cell line technologies, now generating significant IP income.

• Proprietary platforms like WuXia™ enable rapid, high-titer production, reducing IND timelines to ~6 months and increasing yield to 10g/L.

• Digital platforms such as DaVinci Client Portal, BioFoundry, and PatroLab™ digital twin enhance client experience, speed, and operational efficiency.

• Developed technology to convert IV drugs to subcutaneous formulations, enhancing patient convenience.

• Digitalization and AI integration aim for fully automated, paperless manufacturing within three years.